TransAct Technologies Incorporated filed its quarterly report on Form 10-Q for the period ended September 30, 2026, disclosing third-quarter net sales of $14.440 million and a net loss of $440 thousand for the three months ended on that date.
Key Highlights
- Q3 2026 net sales: $14.440 million, compared to $13.176 million in Q3 2025, according to the filing.
- Q3 2026 net loss: $440 thousand, or $(0.04) per basic and diluted share, versus net income of $15 thousand in the prior-year quarter.
- Nine-month net income: $276 thousand, or $0.03 per basic share, on net sales of $42.803 million for the nine months ended September 30, 2026.
- Cash and cash equivalents: $20.214 million as of September 30, 2026, down from $20.433 million at December 31, 2025.
- Total assets: $50.537 million as of September 30, 2026, compared to $44.769 million at December 31, 2025.
- Shares outstanding: 10,338,221 shares of common stock outstanding as of October 31, 2026.
- Operating cash flow: Net cash provided by operating activities was $3.162 million for the nine months ended September 30, 2026.
TransAct Technologies Reports Q3 2026 Financial Results
TransAct Technologies Incorporated (NASDAQ:TACT), a Delaware corporation headquartered in Hamden, Connecticut, reported third-quarter 2026 net sales of $14.440 million, up from $13.176 million in the same quarter of 2025, according to the filing. Gross profit for Q3 2026 was $6.693 million, compared to $6.556 million a year earlier. Total operating expenses rose to $7.108 million in Q3 2026 from $6.542 million in Q3 2025, resulting in an operating loss of $415 thousand versus operating income of $14 thousand in the prior-year period.
For the nine months ended September 30, 2026, the company reported net sales of $42.803 million and net income of $276 thousand, compared to net sales of $40.027 million and a net loss of $109 thousand for the same period in 2025, the filing disclosed. Operating income for the nine-month period was $302 thousand, against an operating loss of $259 thousand in the comparable 2025 period. Share-based compensation expense totaled $1.307 million for the nine months ended September 30, 2026, per the filing.
The balance sheet as of September 30, 2026 showed total assets of $50.537 million, up from $44.769 million at December 31, 2025, with the increase driven in part by higher accounts receivable of $9.868 million and growth in intangible assets, net, to $4.274 million from $1.503 million. Inventories declined to $7.731 million from $10.858 million over the same period. The company reported a revolving loan payable of $3.000 million and total shareholders' equity of $32.480 million as of September 30, 2026. Capitalized software development costs consumed $2.910 million of cash in investing activities for the nine-month period, compared to $1.352 million in the year-ago period.
What Was Disclosed
TransAct Technologies filed a Form 10-Q covering the quarterly period ended September 30, 2026, reporting higher year-over-year net sales for both the third quarter and the nine-month period, a Q3 net loss, positive nine-month net income, and an expanded balance sheet compared to year-end 2025.



Please wait processing your request...